Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
about
Pharmacokinetics of temafloxacin in humans after multiple oral dosesPenetration of fleroxacin into breast milk and pharmacokinetics in lactating womenEvaluation of a novel method to estimate absolute bioavailability of drugs from oral data.Urinary excretion and bactericidal activities of a single oral dose of 400 milligrams of fleroxacin versus a single oral dose of 800 milligrams of pefloxacin in healthy volunteersIn vitro activities of fleroxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumoniaEffect of probenecid on the distribution and elimination of ciprofloxacin in humans.Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studiesPharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.Pharmacokinetics of fleroxacin after multiple oral dosing in patients receiving regular hemodialysis.Pharmacokinetics and metabolism of intravenous and oral fleroxacin in subjects with normal and impaired renal function and in patients on continuous ambulatory peritoneal dialysis.Renal handling of fleroxacin in rabbits, dogs, and humans.Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis.Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patientsTreatment of experimental Salmonella typhimurium infection in mice with fleroxacinEvaluation of fleroxacin (RO 23-6240) as single-oral-dose therapy of culture-proven chancroid in Nairobi, Kenya.Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.Pharmacokinetic studies of CP-74,667, a new quinolone, in laboratory animals.Influence of rifampin on fleroxacin pharmacokinetics.Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.Pharmacokinetics of temafloxacin in humans after single oral doses.Susceptibility of Staphylococcus species and subspecies to fleroxacinEffects of breast pumping on the pharmacokinetics and pharmacodynamics of ethanol during lactationFluoroquinolone disposition: identification of the contribution of renal secretory and reabsorptive drug transporters.Pharmacokinetics of ciprofloxacin with reference to other fluorinated quinolones.Developments in quinolones. Bacteriology, pharmacokinetics and initial clinical experience of several investigational quinolone derivatives.The 4-quinolone antibiotics: past, present, and future.Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.Fleroxacin pharmacokinetics in patients with liver cirrhosisPharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.Comparison of fleroxacin and penicillin G plus probenecid in the treatment of acute uncomplicated gonococcal infections.
P2860
Q24679273-AE97F925-8431-4434-A138-E6B49A2A3762Q24681880-F371F83C-0D43-4889-93C2-93157F7ADE8DQ30760138-900CEBD6-4D55-41B2-BC9B-F473416CB7DEQ33694071-3078FF06-E0A3-48AD-A073-032ECDB19D29Q33744843-00A208BD-FE98-4DC2-9B9F-4EA384972468Q34720221-86752F98-7124-42C9-8AD1-80C2D0089679Q35122861-269FC451-4EEA-4F91-8EBD-A755A2574848Q35123048-68C4258E-48F7-49C6-AF5C-51C57C02003AQ35126187-18B93B6C-4467-4013-BA38-E839DF6BAC04Q35245010-AF35C849-AD8D-48AB-AE88-1684020E359FQ35245673-139FA485-CDC1-47C6-8168-A43F4465DE03Q35250121-6B02F412-A464-42F6-A198-94981C91AAB5Q35276315-8B663317-B00C-465F-8554-B9CD11D0F60DQ35285443-95B657EF-38C8-4BFC-8218-20564FE16AE0Q35307223-B45BBEF1-F04C-43A1-9108-B3F8D5F071EBQ35330665-747E9FB4-F34B-4A29-AF70-381EFCF4E30FQ35821293-76214EDA-A4E5-4AF6-8757-64ACEC7DBCFCQ35893937-08000718-864C-495F-B9C2-A7DAF8FB8FADQ35897356-E0D55EED-A70B-46DA-8014-ED2C6F7A44DEQ35897375-37A10ACF-D79A-4CB2-95B7-957E0EBE527EQ36753040-E5D9C155-A271-44F7-A611-10CE9F157A32Q36756084-1EE696DB-0C35-4F91-B980-D17C80908249Q37288381-4A3D8ACC-694D-4C2E-8F26-DB383337BADFQ37995676-30EA04AA-8EF6-432D-9548-9F13F59887D4Q38271416-A86CC1F6-2F8F-4266-8C63-A1ABFCD4721CQ38635746-431C3AFF-DEB2-4510-A331-6A7CB31A004AQ39314610-E5871C32-FDD7-492F-84CC-E80A19FA0550Q39816007-A9D9FA0D-A115-48BF-B127-5DA8F3C4D9C1Q39816928-81B0FA1C-6E33-47BD-9786-9CD131699429Q39819019-D2671740-85F6-46B8-BE54-E0425326BA72Q39832480-B4C5F03B-91A3-4898-BB2A-269C9F2390F6Q39875877-62D42CF7-3018-4A65-8405-850B9CD80E56Q40088633-07A10C36-DB98-4E01-99B6-EB67C4C2B465Q41943559-EBE5E5E4-8359-42DE-8DC6-67A74724E07B
P2860
Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh
1987年學術文章
@zh-hant
name
Single- and multiple-dose phar ...... orinated quinolone, in humans.
@en
Single- and multiple-dose phar ...... orinated quinolone, in humans.
@nl
type
label
Single- and multiple-dose phar ...... orinated quinolone, in humans.
@en
Single- and multiple-dose phar ...... orinated quinolone, in humans.
@nl
prefLabel
Single- and multiple-dose phar ...... orinated quinolone, in humans.
@en
Single- and multiple-dose phar ...... orinated quinolone, in humans.
@nl
P2093
P2860
P356
P1476
Single- and multiple-dose phar ...... orinated quinolone, in humans.
@en
P2093
P2860
P304
P356
10.1128/AAC.31.12.1909
P407
P577
1987-12-01T00:00:00Z